Distinctive modulation of hepcidin in cancer and its therapeutic relevance

Feng, Lin; Tuffour, Alex; Hao, Guijie; Peprah, Frank Addai; Huang, Aixia; Zhou, Yang; Zhang, Haiqi

doi:10.3389/fonc.2023.1141603

Cited by 2 publications

(1 citation statement)

References 132 publications

(186 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…b. Hepcidin: a small peptide produced by the liver that is able to induce FPN1 degradation to block iron export from cells [8]. Hepcidin is overexpressed in several human tumors, such as breast, lung and prostate cancers, as well as multiple myeloma, for its property to promote neoplastic growth by increasing iron retention in malignant cells [147]. In a breast tumor microenvironment, cancer-associated fibroblasts stimulated hepcidin expression in breast cancer cells via the production of IL-6 [148], while it has been found that hepcidin expression is associated with immune tumor infiltrates in lung cancer, particularly those constituting B cells, CD4 + T cells, macrophages, neutrophils and dendritic cells [149].…”

Section: Other Iron Proteinsmentioning

confidence: 99%

Iron Metabolism in Cancer and Senescence: A Cellular Perspective

Crescenzi

Leonardi

Pacifico

2023

Biology

View full text Add to dashboard Cite

Iron participates in a number of biological processes and plays a crucial role in cellular homeostasis. Alterations in iron metabolism are considered hallmarks of cancer and drivers of aggressive behaviors, such as uncontrolled proliferation, resistance to apoptosis, enhanced metastatic ability, increased cell plasticity and stemness. Furthermore, a dysregulated iron metabolism has been associated with the development of an adverse tumor microenvironment. Alterations in iron metabolism have been described in cellular senescence and in aging. For instance, iron has been shown to accumulate in aged tissues and in age-related diseases. Furthermore, in vitro studies demonstrate increases in iron content in both replicative and stress-induced senescent cells. However, the role, the mechanisms of regulation and dysregulation and the effects of iron metabolism on senescence remain significantly less characterized. In this review, we first provide an overview of iron metabolism and iron regulatory proteins. Then, we summarize alterations in iron homeostasis in cancer and senescence from a cellular point of view.

show abstract

Section: Other Iron Proteinsmentioning

confidence: 99%

Iron Metabolism in Cancer and Senescence: A Cellular Perspective

Crescenzi

Leonardi

Pacifico

2023

Biology

View full text Add to dashboard Cite

show abstract

The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

Kontoghiorghes

2024

IJMS

View full text Add to dashboard Cite

The supply and control of iron is essential for all cells and vital for many physiological processes. All functions and activities of iron are expressed in conjunction with iron-binding molecules. For example, natural chelators such as transferrin and chelator–iron complexes such as haem play major roles in iron metabolism and human physiology. Similarly, the mainstay treatments of the most common diseases of iron metabolism, namely iron deficiency anaemia and iron overload, involve many iron–chelator complexes and the iron-chelating drugs deferiprone (L1), deferoxamine (DF) and deferasirox. Endogenous chelators such as citric acid and glutathione and exogenous chelators such as ascorbic acid also play important roles in iron metabolism and iron homeostasis. Recent advances in the treatment of iron deficiency anaemia with effective iron complexes such as the ferric iron tri-maltol complex (feraccru or accrufer) and the effective treatment of transfusional iron overload using L1 and L1/DF combinations have decreased associated mortality and morbidity and also improved the quality of life of millions of patients. Many other chelating drugs such as ciclopirox, dexrazoxane and EDTA are used daily by millions of patients in other diseases. Similarly, many other drugs or their metabolites with iron-chelation capacity such as hydroxyurea, tetracyclines, anthracyclines and aspirin, as well as dietary molecules such as gallic acid, caffeic acid, quercetin, ellagic acid, maltol and many other phytochelators, are known to interact with iron and affect iron metabolism and related diseases. Different interactions are also observed in the presence of essential, xenobiotic, diagnostic and theranostic metal ions competing with iron. Clinical trials using L1 in Parkinson’s, Alzheimer’s and other neurodegenerative diseases, as well as HIV and other infections, cancer, diabetic nephropathy and anaemia of inflammation, highlight the importance of chelation therapy in many other clinical conditions. The proposed use of iron chelators for modulating ferroptosis signifies a new era in the design of new therapeutic chelation strategies in many other diseases. The introduction of artificial intelligence guidance for optimal chelation therapeutic outcomes in personalised medicine is expected to increase further the impact of chelation in medicine, as well as the survival and quality of life of millions of patients with iron metabolic disorders and also other diseases.

show abstract

Distinctive modulation of hepcidin in cancer and its therapeutic relevance

Cited by 2 publications

References 132 publications

Iron Metabolism in Cancer and Senescence: A Cellular Perspective

Iron Metabolism in Cancer and Senescence: A Cellular Perspective

The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency

Contact Info

Product

Resources

About